Orthocell (ASX:OCC) achieved the first commercial sales of its nerve repair product, Remplir, in Hong Kong, to pharmaceutical firm MontsMed, according to a Wednesday filing with the Australian bourse.
The company expects to start selling Remplir in Canada and Thailand in the near term, the filing said.